Authors:
SHAMREY V.K., KURASOV E.S., NECHIPORENKO V.V., KOLCHEV A.I., TSYGAN N.V.
FGBVOU in the "Military Medical Academy named after CM. Kirov ”, St. Petersburg, Russia
Authors:
SHAMREY V.K., KURASOV E.S., NECHIPORENKO V.V., KOLCHEV A.I., TSYGAN N.V.
FGBVOU in the "Military Medical Academy named after CM. Kirov ”, St. Petersburg, Russia
Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2020, Vol. 120, No. 5
Abstract: This article
presents a review of the current literature on the use of Mexidol (ethylmethylhydroxypyridine succinate) in the treatment of mental disorders (including addictive disorders). It demonstrates its potential for correcting negative psychopathological symptoms, neurocognitive deficits, and manifestations of neuroleptic syndrome (including extrapyramidal disturbances) during antipsychotic treatment in patients with schizophrenia spectrum disorders, as well as insomnia in combination therapy for borderline mental disorders. Of particular note are Mexidol's potential use in the treatment of addictive disorders and the effects of alcohol and other psychoactive substance intoxication (including narcotic substances). Key words: mental disorders, addictive disorders, Mexidol, treatment, combination therapy.
THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.
Source of photos and images Shutterstock.com